Price T Rowe Associates Inc. MD Purchases 922 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Price T Rowe Associates Inc. MD grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 5.7% in the first quarter, Holdings Channel.com reports. The fund owned 17,004 shares of the biotechnology company’s stock after buying an additional 922 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Arcturus Therapeutics were worth $575,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of ARCT. SummerHaven Investment Management LLC lifted its position in shares of Arcturus Therapeutics by 1.7% during the 4th quarter. SummerHaven Investment Management LLC now owns 22,704 shares of the biotechnology company’s stock worth $716,000 after buying an additional 378 shares during the period. CANADA LIFE ASSURANCE Co lifted its position in shares of Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock worth $152,000 after buying an additional 428 shares during the period. Formidable Asset Management LLC lifted its position in shares of Arcturus Therapeutics by 3.3% during the 4th quarter. Formidable Asset Management LLC now owns 15,550 shares of the biotechnology company’s stock worth $490,000 after buying an additional 500 shares during the period. BNP Paribas Financial Markets raised its position in Arcturus Therapeutics by 3.0% in the 4th quarter. BNP Paribas Financial Markets now owns 23,259 shares of the biotechnology company’s stock valued at $733,000 after purchasing an additional 682 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its position in Arcturus Therapeutics by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after purchasing an additional 778 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ARCT. HC Wainwright lifted their price objective on Arcturus Therapeutics from $60.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Tuesday, August 6th. Canaccord Genuity Group cut their price objective on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a research report on Friday, May 10th. SVB Leerink assumed coverage on Arcturus Therapeutics in a research report on Monday. They issued an “outperform” rating and a $70.00 price objective for the company. Finally, William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $68.50.

Insider Buying and Selling

In related news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the sale, the chief operating officer now directly owns 447,448 shares of the company’s stock, valued at $17,902,394.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 13.80% of the stock is owned by insiders.

Arcturus Therapeutics Stock Up 3.8 %

Shares of Arcturus Therapeutics stock opened at $19.67 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 12 month low of $17.52 and a 12 month high of $45.00. The business has a fifty day simple moving average of $25.33 and a 200 day simple moving average of $30.50. The stock has a market cap of $529.75 million, a PE ratio of -5.03 and a beta of 2.64.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 37.61% and a negative net margin of 81.59%. The business had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. During the same period in the previous year, the firm earned ($1.98) earnings per share. Analysts expect that Arcturus Therapeutics Holdings Inc. will post -4.74 EPS for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.